Lung cancer has the highest incidence among all malignant tumors in China, with a very high mortality rate, making its treatment and comprehensive management a major focus of attention. To further advance the development of lung cancer diagnosis and treatment disciplines, promote precision diagnosis and standardized treatment of lung cancer, improve the quality of life for lung cancer patients, and enhance the multidisciplinary diagnostic and therapeutic capabilities in the field of lung cancer treatment, the "Immunotherapy 2.0 Era - Lung Cancer Special Seminar," jointly organized by the Gansu Medical Association and the Chengdu High-Tech Zone Medical Association, was successfully held on July 26, 2025.

The seminar primarily brought together multidisciplinary healthcare professionals from oncology, respiratory medicine, thoracic surgery, radiotherapy, pathology, and imaging departments. Focusing on topics such as standardized lung cancer diagnosis and treatment, adverse reaction management, and the latest advancements in lung cancer therapy, the event aimed to establish a high-level academic exchange platform, drive the development of related healthcare initiatives, and foster academic collaboration, interdisciplinary integration, as well as academic and industrial translation.